Metastasis of breast cancers is a common and serious clinical problem, with up to one third of women with earlystage breast cancer eventually dying of the disease. Of all patients with distant spread of the cancer, 70% have bone metastases (1,2), reflective of the observations of Paget (3) that breast cancers had a particular predilection to grow in bone. A special property required of cancer cells for growth as metastases in bone is the ability to promote bone resorption by inducing the formation and activity of osteoclasts (4). Parathyroid hormone-related protein (PTHrP) is produced by two thirds of primary breast cancers (5), promotes osteoclast formation and bone resorption, and has been implicated in site-specific metastasis of breast cancer to bone (6). The current study investigated the relationship among detection of PTHrP in primary breast cancers, development of skeletal complications, and overall survival.
Metastasis of breast cancers is a common and serious clinical problem, with up to one third of women with earlystage breast cancer eventually dying of the disease. Of all patients with distant spread of the cancer, 70% have bone metastases (1, 2) , reflective of the observations of Paget (3) that breast cancers had a particular predilection to grow in bone. A special property required of cancer cells for growth as metastases in bone is the ability to promote bone resorption by inducing the formation and activity of osteoclasts (4) . Parathyroid hormone-related protein (PTHrP) is produced by two thirds of primary breast cancers (5) , promotes osteoclast formation and bone resorption, and has been implicated in site-specific metastasis of breast cancer to bone (6) . The current study investigated the relationship among detection of PTHrP in primary breast cancers, development of skeletal complications, and overall survival.
From December 1, 1989 , through December 31, 1994, a total of 402 consecutively accrued women with operable (stages 1-3) invasive primary breast cancer were followed prospectively for a median period of 67 months (range, 3-120 months). Impalpable tumors detected by screening mammography accounted for 5% of the cancers. Patients with previous malignancy or preoperative therapy before open biopsy were excluded (35 patients). The timing and site of metastases and overall survival were recorded, as were routine prognostic factors. Patients were examined at least twice a year for 3 years and then annually. The study was approved by the Human Research Ethics Committee of St. Vincent's Hospital (Fitzroy, Australia), and patients provided informed consent according to institutional guidelines.
There were 367 eligible patients, and the median age at diagnosis was 60 years (range, 27-92 years). The majority of these patients were postmenopausal (70%), the median tumor size was 26 mm (range, 4-180 mm), and most patients were axillary lymph node negative (60%) ( (Fig. 1, A) (8, 9) . The crude 5-year cancer-specific survivals were 87% (95% CI ‫ס‬ 82% to 91%) for patients with PTHrP-positive tumors and 73% (95% CI ‫ס‬ 63% to 81%) for those with PTHrP-negative tumors (P ‫ס‬ .002). Cox proportional hazards modeling (10) demonstrated that positive PTHrP status was independently associated with improved survival (P ‫ס‬ .003), as were the number of axillary lymph nodes involved (P<.001), tumor size (P<.001), and tumor grade (P ‫ס‬ .007). After adjustment for these independently predictive prognostic factors, the hazard rate for death from breast cancer in women with a PTHrP-positive tumor was 45% (95% CI ‫ס‬ 26% to 80%) of that in women with a PTHrP-negative tumor (P ‫ס‬ .003) (10) . All statistical tests were two-sided.
Patients with PTHrP-positive primary cancers were less likely to develop bone metastases at any time during observation after surgery (Fig. 1, B) (8, 9 (10) demonstrated that absence of PTHrP staining in the primary tumor was independently predictive of bone metastases (P ‫ס‬ .002), as was the number of axillary lymph nodes involved with tumor (P<.001), the presence of lymphatic/vascular invasion (P ‫ס‬ .002), and the absence of PR staining (P ‫ס‬ .04). After adjustment for these independently predictive prognostic fac- (7) 11 (11) .4
*Mastectomy with axillary lymphadenectomy was performed in 217 (59%) patients, segmental mastectomy with axillary lymphadenectomy in 139 (38%), and less than mastectomy without lymphadenectomy in 11 (3%). There was no difference in parathyroid-related hormone protein (PTHrP) status among the three surgical treatment groups. Nine patients received preoperative chemotherapy, and one received preoperative radiotherapy. Postoperative adjuvant chemotherapy was given to 130 patients, adjuvant radiotherapy was given to 141, and tamoxifen was given postoperatively to 201. Some patients received more than one adjuvant therapy. There was no difference in PTHrP status among these treatment groups.
†PTHrP was localized by use of a standard peroxidase-antiperoxidase method (20) , with polyclonal rabbit antiserum raised to the human PTHrP peptide containing amino acids 1-14 [PTHrP (1-14) ]. The antiserum specificity has been characterized (21, 22) , and no cross-reactivity with parathyroid hormone was observed under any condition examined, including western blotting. The following methods and antibody controls were used: alternating deletion of the antibody layers, preabsorption of anti-PTHrP (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) overnight with peptide at 4°C, application of PTHrP(1-14) at 0.5 mg/mL to the tissue sections 5 minutes before the addition of the antiserum, and replacement of the anti-PTHrP(1-14) with nonimmune rabbit serum. Each assay included a positive control (normal skin). Each tumor section was stained in duplicate, with two dilutions of antisera, and was assessed by a panel of individuals who were unaware of the clinical details. Tumors were called positive for PTHrP when specific staining was observed in any cell that was unequivocally identified as a tumor cell. In addition, a random series of samples (8%) that had been reviewed previously by the panel were restained and evaluated as an internal control of assessment. There was 100% concordance with the original assessments. The assay was repeated if there was substantial background staining on the nonimmune control, if there was discordance between the two stained sections, or if there was a lack of agreement among panel members. In all positive tumors, a cytoplasmic pattern was found. In 20% of these tumors, some specific membrane staining was also noted. ‡Statistical analysis: Differences between groups were assessed by standard contingency table analysis, including Fisher's exact test for binary or categorical variables, and by the Mann-Whitney U test for continuous variables, as appropriate. The strength of association between binary variables was measured by the odds ratio, with exact 95% confidence interval calculated as described previously by Mehta (7). All reported statistical significance levels are nominal and two-sided; following convention, those less than .05 are considered to be statistically significant.
§Tumor size was classified according to the criteria of the American Joint Commission on Cancer (AJCC) (23) . T1a is a tumor of 5 mm or less, T1b is a tumor greater than 5 mm but not more than 10 mm, T1c is a tumor greater than 10 mm but not greater than 20 mm, T2 is a tumor greater than 20 mm but not greater than 50 mm, T3 is a tumor greater than 50 mm, and T4 is any tumor with a direct extension to skin or chest wall. Tumor size was available for 365 patients.
N0 is no axillary lymph node metastasis. N1 is spread to one or more axillary lymph nodes without fixation to other lymph nodes or adjacent structures. Formal axillary dissection was not performed for 11 patients. Axillary lymph node status was available for 344 patients.
¶The patients' disease was staged according to the AJCC classification (23) . Stage 1 ‫ס‬ T1 N0, stage 11a ‫ס‬ T2 N0, T1 N1, stage 11b ‫ס‬ T2 N1, T3 N0, and stage 3 ‫ס‬ T3 N1, T4 N0 or N1. Staging was available in 343 cases. #Before 1992, estrogen receptor (ER) status and progesterone receptor (PR) status were determined by competitive radioligand assay. After 1992, ER and PR were assayed immunohistochemically on sections from formalin-fixed, paraffin-embedded tumors with the use of commercially available antibodies (NCL-ER-6F11 and NCL-PR; Novocastra Laboratories Ltd., Newcastle-Upon-Tyne, U.K.). For patients entering the study before 1992, ER status and PR status were subsequently determined immunohistochemically if there was sufficient representative material available. Tumors were called positive for ER or PR when 10% or more of the tumor cells showed unequivocal nuclear staining. ER status was available for 345 patients, and PR status was available for 324 patients. Both ER status and PR status were associated with PTHrP status. **Tumors were graded by the modified Bloom and Richardson classification (24) . Grade 1 is a well-differentiated tumor, grade 2 is a moderately differentiated tumor, and grade 3 is a poorly differentiated tumor. Twenty-six lobular cancers, which are not normally graded, were classified as grade 2 or moderately differentiated.
† †Tumor calcification, recognized on routine microscopy, was associated with PTHrP status. ‡ ‡Special tumor types included tubular, medullary, and papillary tumors and all were of low grade.
tors, the hazard rate for development of bone metastases in women with PTHrPpositive tumors was 39% (95% CI ‫ס‬ 21% to 71%; P ‫ס‬ .002) (10) of that in women with a PTHrP-negative tumor. This study was carried out over a 10-year period as a prospective investigation of consecutively accrued patients.
Consistent with previous reports (5, (11) (12) (13) (14) (15) , approximately two thirds of primary breast tumors contained detectable PTHrP. The new finding is that PTHrP localization in female breast tumors is an independent predictor of improved survival and reduced risk of metastases, whether or not adjustment is made for the recognized prognostic factorsaxillary lymph node status, tumor size, tumor grade, and ER and PR status. These observations are contrary to our original hypothesis and indicate that PTHrP-negative cancers are associated with more metastases and less favorable survival. Thus, we conclude that PTHrP production is associated with a less invasive phenotype. A direct causal link remains to be established. Because these results were obtained before the introduction of screening mammography, the importance of PTHrP in very early breast cancer needs to be and is currently being addressed.
When the study began, we hypothesized that patients with PTHrP-positive breast cancers would be more likely to develop bone metastases. In the intervening time, experimental support has been obtained for a local role of PTHrP in bone metastasis formation (16) . More frequent and larger bone metastases were found in a nude mouse model of bone metastasis when human breast cancer cells expressing PTHrP were used (16) (17) (18) . Concurrent treatment with bisphosphonates, which are powerful inhibitors of bone resorption, or with neutralizing antibody against PTHrP reduced both the size and the number of metastases in this model (16, 17) .
The present findings, however, do not exclude a central role for PTHrP in the bone metastasis process. Specific properties of the "soil," or bone microenvironment, for successful establishment of metastases and regulation of PTHrP production have been described. The role of the bone microenvironment is emphasized by studies in the nude mouse model, in which transforming growth factor-␤ a powerful stimulator of PTHrP production (18, 19) released during tumor invasion, increases local PTHrP production by breast cancer cells, thereby promoting bone resorption and facilitating tumor growth.
We conclude that women with PTHrP-positive primary breast cancers have a more favorable outcome and have fewer metastases to bone and other . O ‫ס‬ number of observed events. Differences in survival were assessed by the log-rank test (P ‫ס‬ .002) (8, 9) . The numbers of patients at risk in each group at successive survival times are shown. Subjects were considered to have died of breast cancer if there was objective evidence of metastases before death. Bone metastasis was confirmed by x-ray and scintigraphy in patients with bone pain or fracture. Local and regional recurrences were confirmed histologically. Recurrences at other accessible sites (e.g., supraclavicular lymph nodes, distant lymph node recurrence, and pleural effusion or ascites fluid) were confirmed by cytologic examination. Other sites of metastasis were confirmed by appropriate imaging. The mean length of follow-up was 70 months, and the median follow-up was 67 months (range, 3-120 months). At follow-up, 15 patients were alive with metastatic disease, 66 had died of breast cancer, and 22 had died of other causes without any evidence of recurrent breast cancer. The crude 5-year cancer-specific survivals were 87% (95% confidence interval [CI] ‫ס‬ 82% to 91%) for patients with PTHrP-positive tumors and 73% (95% CI ‫ס‬ 63% to 81%) for those with PTHrP-negative tumors. B) Curves for cumulative risk for development of bone metastases as a function of time from diagnosis. Survival was compared for patients with PTHrP-positive tumors (N ‫ס‬ 265) and patients with PTHrP-negative tumors (N ‫ס‬ 102). Differences in survival were assessed by the log-rank test (P ‫ס‬ .001) (8, 9) . The crude cumulative 5-year risk for the development of bone metastases was 26% (95% CI ‫ס‬ 19% to 37%) for patients with PTHrP-negative primary tumors and 13% (95% CI ‫ס‬ 9% to 18%) for those with PTHrP-positive tumors. All statistical tests were two-sided.
sites. The nature of autocrine actions of PTHrP in primary breast tumors that contribute to this favorable outcome would be of considerable interest, and attention should now be focused on how PTHrP contributes to this protective effect against invasion and metastasis. The greater frequency of bone metastases in patients with PTHrP-negative primary breast cancers remains consistent with a local role for PTHrP in the development of bone metastases because the bone microenvironment has the potential to promote tumor cell production of PTHrP.
